Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for this condition, were typically of only 3- to 6-months' duration. We have limited data on long-term (that is, a year or more) therapy with these agents. In this review, we explore the available information on the biological and clinical effects of long-term ChEI therapy, what happens when these agents are discontinued, and examine what others have recommended. An individualized approach to deciding on whether to carry on with a ChEI should be taken. If continued, treatment goals should be clarified and patients monitored over time, for both drug-related benefits and adverse effects.
Canadian Institute for Health Information (CIHI). Drug use among seniors on public drug programs in Canada, 2012. Ottawa (ON): CIHI; 2014.
2.
RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–397.
3.
WolfsonCWolfsonDBAsgharianM; On behalf of the Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111–1116.
4.
HerrmannNGillSSBellCMA population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55:1517–1523.
5.
AmuahJEHoganDBEliasziwMPersistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19:670–679.
6.
QaseemASnowVCrossJTCurrent pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370–378.
SmithAKobayashiKChappellNThe controversial promises of cholinesterase inhibitors for Alzheimer's disease and related dementias: A qualitative study of caregivers' experiences. J Aging Stud. 2011;25:397–406.
9.
DaviesPMaloneyAJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2(8000):1403.
10.
BartusRTDeanRL3rdBeerBThe cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–417.
11.
SchneiderLSMangialascheFAndreasenNClinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. J Intern Med. 2014;275:251–283.
12.
FrancisPTPalmerAMSnapeMThe cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137–147.
13.
SeltzerB.Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?Drugs Aging. 2007;24:881–890.
14.
ShanksMKivipeltoMBullockRCholinesterase inhibition: Is there evidence for disease-modifying effects?Curr Med Res Opin. 2009;25:2439–2446.
15.
NizriEHamra-AmitayYSicsicCAnti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology. 2006;50:540–547.
16.
NordbergA.Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(Suppl 1):S12–S18.
17.
CraigLAHongNSMcDonaldRJ. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev. 2011;35:1397–1409.
18.
SallowaySMintzerJWeinerMFDisease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008;4:65–79.
19.
ParnettiLAmiciSLanariACerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci. 2002;23(Suppl 2):S95–S96.
20.
BlennowKZetterbergHMinthonLLongitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419:18–22.
21.
ParnettiLChiasseriniDAndreassonUChanges in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurol Scand. 2011;124:122–129.
22.
ChalmersKAWilcockGKVintersHVCholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol. 2009;256:717–720.
23.
Darreh-ShoriTSoininenH.Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: A review of recent clinical studies. Curr Alzheimer Res. 2010;7:67–73.
24.
MohsRCDoodyRSMorrisJCA 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488.
25.
WinbladBEngedalKSoininenHA 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489–495.
26.
CourtneyCFarrellDGrayRLong-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomized double-blind trial. Lancet. 2004;363:2105–2115.
27.
SuhG-HJungHYLeeCU; For the Korean Galantamine Study Group. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: A 52-week prospective Study. J Korean Med Sci. 2008;23:10–17.
28.
HowardRMcShaneRLindesayJDonepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366:893–903.
29.
WattmoC.Prediction models for assessing long-term outcome in Alzheimer's disease: A review. Am J Alzheimers Dis Other Dement. 2013;28:440–449.
30.
RountreeSDChanWPavlikVNPersistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:7.
31.
RountreeSDAtriALopezOLEffectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013;9:338–345.
32.
FinucaneTE. Another advertisement for donepezil. J Am Geriatr Soc. 2004;52:843.
33.
RoyallDR. Donepezil's effects remain uncertain. J Am Geriatr Soc. 2004;52:843–845.
34.
KarawishJHT. Donepezil delay to nursing home placement study is flawed. J Am Geriatr Soc. 2004;52:845.
35.
SchneiderLS. Open-label extension studies and misinformation. Arch Neurol. 2006;63:1036.
36.
SchneiderLS. Could cholinesterase inhibitors be harmful over the long term?Int Psychogeriatr. 2012;24:171–174.
37.
WinbladBWimoAEngedalK3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21:353–363.
38.
CummingsJL. What we can learn from open-label extensions of randomized clinical trials. Arch Neurol. 2006;63:18–19.
39.
SchneiderLSInselPSWeinerMW; For the Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58–66.
40.
SonaAZhangPAmesDPredictors of rapid cognitive decline in Alzheimer's disease: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of Ageing. Int Psychogeriatr. 2012;24:197–204.
SinkKMThomasJ3rdXuHDual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56:847–853.
43.
GillSSAndersonGMFischerHDSyncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population based cohort study. Arch Intern Med. 2009;169:867–873.
44.
HernandezRKFarwellWCantorMDCholinesterase inhibitors and hospitalizations for bradycardia. J Am Geriatr Soc. 2009;57:1997–2003.
45.
Park-WylieLYMamdaniMMLiPCholinesterase inhibitors and hospitalizations for bradycardia. PLoS Med. 2009;6:e1000157. doi: 10.1371/journal.pmed.1000157. Epub 2009 Sep 29.
46.
KimDHBrownRTDingELDementia medications and risk of falls, syncope, and related adverse events meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59:1019–1031.
47.
HowesLG. Cardiovascular effects of drugs used to treat Alzheimer's disease. Drug Saf. 2014;37:391–395.
48.
RowlandJPRigbyJHarperACCardiovascular monitoring with acetylcholinesterase inhibitors: A clinical protocol. Adv Psychiatr Treat. 2007;13:178–184.
49.
YapYGCammAJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–1372.
50.
LeitchAMcGinnessPWallbridgeD.Calculate the QT interval in patients taking drugs for dementia. BMJ. 2007;335:557.
51.
HelouRRhalimiM.Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients. J Popul Ther Clin Pharmacol. 2010;17:e379–e389. Epub 2010 Oct 26.
52.
StephensonASeitzDPFischerHDCholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: A population-based, cohort study. Drugs Aging. 2012;29:213–223.
53.
ThavornKGomesTCamachoXUpper gastrointestinal bleeding in elderly adults with dementia receiving cholinesterase inhibitors: A population-based cohort study. J Am Geriatr Soc. 2014;62:382–384.
54.
TamuraBKMasakiKHBlanchetteP.Weight loss in patients with Alzheimer's disease. J Nutr Elder. 2007;26:21–38.
55.
StewartJTGorelikAR. Involuntary weight loss associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2006;54:1013–1014.
56.
Gillette-GuyonnetSCortesFCantetC; On behalf of the REAL.FR Group. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: Data from the French REAL.FR cohort. J Nutr Health Aging. 2005;9:69–73.
57.
DroogsmaEvan AsseltDZvan SteijnJHEffect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. J Nutr Health Aging. 2013;17:461–465.
58.
ZannasASOkunoYDoraiswamyPM. Cholinesterase inhibitors and Pisa syndrome: A pharmacovigilence study. Pharmacotherapy. 2014;34:272–278.
59.
TavassoliNSommetALapeyre-MestreMDrug interactions with cholinesterase inhibitors: An analysis of the French pharmacovigilence database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf. 2007;30:1063–1071.
60.
SinghSDudleyC.Discontinuation syndrome following donepezil discontinuation. Int J Geriatr Psychiatry. 2003;18:282–284.
61.
BidzanLBidzanM.Withdrawal syndrome after donepezil cessation in a patient with dementia. Neurol Sci. 2012;33:1459–1461.
62.
MinettTSThomasAWilkinsonLMWhat happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:988–993.
63.
DaielloLAOttBRLapaneKLEffect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7:74–83.
64.
ScarpiniEBrunoGZappalàGCessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: A randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011;26:211–220.
65.
ClinicalTrials.gov. Discontinuation of cholinesterase inhibitors for the treatment of severe Alzheimer's disease [Internet]. Bethesda (MD): National Institutes of Health;2013 Nov 25 [updated 2014 Jan 13; cited 2014 Jun 9]. Available from: http://clinicaltrails.gov/show/NCT02035982.
66.
HerrmannNLanctôtKLHoganDB. Pharmacological recommendations for the symptomatic treatment of dementia: The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer Res Ther. 2013;5(Suppl 1):S5.
67.
DoodyRSGeldmacherDSGordonB; For the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol. 2001;58:427–433.
68.
ParienteAFourrier-RéglatABazinFEffect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957–963.
69.
HerrmannNBlackSELiADiscontinuing cholinesterase inhibitors: Results of a survey of Canadian dementia experts. Int Psychogertiatr. 2011;23:539–545.
70.
HanLColeMBellavanceFTracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr. 2000;12:231–247.
71.
JonesRWSchwamEWilkinsonDRates of cognitive change in Alzheimer disease—observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord. 2009;23:357–364.
72.
ClarkCMSheppardLFillenbaumGGVariability in annual Mini-Mental State Examination score in patients with probable Alzheimer's disease. Arch Neurol. 1999;56:857–862.
73.
FillitHMDoodyRSBinasoKRecommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006;4(Suppl A):S9–S24.
74.
National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217. London (GB): NICE; 2011.
75.
IhlRFrölichLWinbladBWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry. 2011;12:2–32.
76.
HoganDBBaileyPBlackSDiagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179:787–793.
77.
PerraultAWolfsonCEganMPrognostic factors for functional independence in older adults with mild dementia: Results from the Canadian study of health and aging. Alzheimer Dis Assoc Disord. 2002;16:239–247.
